EA201691759A1 - Композиции и способы лечения легочной гипертензии - Google Patents

Композиции и способы лечения легочной гипертензии

Info

Publication number
EA201691759A1
EA201691759A1 EA201691759A EA201691759A EA201691759A1 EA 201691759 A1 EA201691759 A1 EA 201691759A1 EA 201691759 A EA201691759 A EA 201691759A EA 201691759 A EA201691759 A EA 201691759A EA 201691759 A1 EA201691759 A1 EA 201691759A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
pulmonary hypertension
treatment
pharmaceutically acceptable
Prior art date
Application number
EA201691759A
Other languages
English (en)
Inventor
Луис Белардинелли
Хантер Кэмпбелл Джиллис
Фацюань Лянг
Джон Шриок
Суя Янг
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691759(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201691759A1 publication Critical patent/EA201691759A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В настоящем изобретении предложены составы, содержащие терапевтически эффективные количества амбризентана или его фармацевтически приемлемой соли и тадалафила или его фармацевтически приемлемой соли, и способы лечения и/или предотвращения легочной гипертензии путем введения указанных составов.
EA201691759A 2010-10-15 2011-10-14 Композиции и способы лечения легочной гипертензии EA201691759A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39352910P 2010-10-15 2010-10-15
US201161490454P 2011-05-26 2011-05-26
US201161497475P 2011-06-15 2011-06-15

Publications (1)

Publication Number Publication Date
EA201691759A1 true EA201691759A1 (ru) 2017-05-31

Family

ID=45939010

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390428A EA026074B1 (ru) 2010-10-15 2011-10-14 Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
EA201691759A EA201691759A1 (ru) 2010-10-15 2011-10-14 Композиции и способы лечения легочной гипертензии

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201390428A EA026074B1 (ru) 2010-10-15 2011-10-14 Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии

Country Status (25)

Country Link
US (3) US20120269898A1 (ru)
EP (2) EP2637664B1 (ru)
JP (2) JP5806320B2 (ru)
KR (2) KR20150002876A (ru)
CN (1) CN103458690B (ru)
AR (1) AR083422A1 (ru)
AU (2) AU2011315891B2 (ru)
BR (1) BR112013008983A2 (ru)
CA (1) CA2814518C (ru)
CY (1) CY1119007T1 (ru)
DK (1) DK2637664T3 (ru)
EA (2) EA026074B1 (ru)
ES (1) ES2627944T3 (ru)
HR (1) HRP20170848T1 (ru)
HU (1) HUE033346T2 (ru)
LT (1) LT2637664T (ru)
MX (1) MX346730B (ru)
NZ (2) NZ707213A (ru)
PL (1) PL2637664T3 (ru)
PT (1) PT2637664T (ru)
RS (1) RS56135B1 (ru)
SI (1) SI2637664T1 (ru)
TW (1) TWI542580B (ru)
WO (1) WO2012051559A2 (ru)
ZA (1) ZA201302746B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101777T3 (en) 2006-12-12 2015-08-17 Gilead Sciences Inc COMPOSITION FOR TREATMENT OF PULMONAL HYPERTENSION
EP2637664B1 (en) 2010-10-15 2017-03-29 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
WO2015069839A1 (en) * 2013-11-06 2015-05-14 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
CA2982436C (en) * 2015-03-13 2023-09-12 Indiana University Research And Technology Corporation Targeting cgmp-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
BR112019000790A2 (pt) 2016-07-15 2019-07-02 Acceleron Pharma Inc composições e métodos para tratar hipertensão pulmonar
MX2019004855A (es) * 2016-10-27 2019-09-19 Pulmokine Inc Politerapia para tratar hipertension pulmonar.
WO2019010445A1 (en) * 2017-07-07 2019-01-10 The Regents Of The University Of Colorado, A Body Corporate COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION
BR112020012986A2 (pt) * 2017-12-26 2020-12-01 Ftf Pharma Private Limited formulações orais líquidas para inibidores de pde v
CN109406688A (zh) * 2018-09-28 2019-03-01 中国食品药品检定研究院 用于检测产品中违禁药品的标准样品
TW202133851A (zh) * 2019-11-29 2021-09-16 瑞士商艾克泰聯製藥有限公司 治療肺動脈高血壓之方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
ATE213246T1 (de) 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
EP1776108A1 (en) 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (zh) * 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
WO2007122466A1 (en) 2006-04-21 2007-11-01 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
CA2669535A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorders
DK2101777T3 (en) * 2006-12-12 2015-08-17 Gilead Sciences Inc COMPOSITION FOR TREATMENT OF PULMONAL HYPERTENSION
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
EP2637664B1 (en) 2010-10-15 2017-03-29 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension

Also Published As

Publication number Publication date
CA2814518A1 (en) 2012-04-19
CN103458690A (zh) 2013-12-18
WO2012051559A3 (en) 2013-10-17
CA2814518C (en) 2016-09-20
ZA201302746B (en) 2014-06-25
JP2015178528A (ja) 2015-10-08
KR20150002876A (ko) 2015-01-07
MX2013004190A (es) 2013-07-29
HUE033346T2 (en) 2017-11-28
PT2637664T (pt) 2017-06-22
PL2637664T3 (pl) 2017-09-29
US20140275098A1 (en) 2014-09-18
EP2637664A2 (en) 2013-09-18
MX346730B (es) 2017-03-30
EA201390428A1 (ru) 2014-02-28
RS56135B1 (sr) 2017-10-31
EP3106163A1 (en) 2016-12-21
ES2627944T3 (es) 2017-08-01
US20120269898A1 (en) 2012-10-25
AU2016204638B2 (en) 2018-06-07
EA026074B1 (ru) 2017-02-28
DK2637664T3 (en) 2017-06-19
BR112013008983A2 (pt) 2016-07-05
TW201219372A (en) 2012-05-16
KR20130069855A (ko) 2013-06-26
TWI542580B (zh) 2016-07-21
US20160346280A1 (en) 2016-12-01
AU2011315891A1 (en) 2013-05-23
HRP20170848T1 (hr) 2017-08-25
NZ707213A (en) 2016-12-23
CY1119007T1 (el) 2018-01-10
LT2637664T (lt) 2017-11-10
US9549926B2 (en) 2017-01-24
JP2014506870A (ja) 2014-03-20
AU2011315891B2 (en) 2015-08-13
AR083422A1 (es) 2013-02-21
SI2637664T1 (sl) 2017-07-31
EP2637664A4 (en) 2014-09-10
EP2637664B1 (en) 2017-03-29
CN103458690B (zh) 2016-03-16
WO2012051559A2 (en) 2012-04-19
JP5806320B2 (ja) 2015-11-10
AU2016204638A1 (en) 2016-08-04
NZ610012A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201690752A1 (ru) Ингибиторы g12c kras
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
NZ708501A (en) Treatment of pulmonary disease
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
NZ703064A (en) Inhibitors of hepatitis c virus
EA201290632A1 (ru) Производные бетулина
EA201070786A1 (ru) Бензофуропиримидиноны
EA201300862A1 (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX348726B (es) Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена